Atlas FDA

IMMULITE 2000 XPI ANTI-HBC

FDA premarket approval P010051 · decided 2002-07-24

Approval details

PMA number
P010051
Trade name
IMMULITE 2000 XPI ANTI-HBC
Generic name
Qualitative and Quantitative Hepatitis B Virus Antibody assays
Applicant
Siemens Healthcare Diagnostics Products, Ltd.
Date received
2001-08-31
Decision date
2002-07-24
Days to decision
327 days
Decision code
APRL
Product code
SEI
Advisory committee
Microbiology
Expedited review
No
Location
Llanberis
Statement
APPROVAL FOR THE IMMULITE ANTI-HBC AND IMMULITE 2000 ANTI-HBC. THESE DEVICES ARE INDICATED FOR: IMMULITE. ANTI-HBC: IMMULITE ANTI-HBC IS A SOLID -PHASE CHEMILUMINESCENT ENZYME IMMUNOASSAY DESIGNED FOR USE ON THE IMMULITE AUTOMATED IMMUNOASSAY ANALYZER FOR THE QUALITATIVE DETECTION OF TOTAL ANTIBODIES AGAINST HEPATITIS B CORE ANTIGEN (ANTI-HBC) IN HUMAN SERUM OR PLASMA (EDTA, HEPARINIZED, CITRATE). IT IS INTENDED FOR IN VITRO DIAGNOSTIC USE FOR THE LABORATORY DIAGNOSIS OF ONGOING OR PREVIOUS HEPA

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.

510(k) clearances by this applicant

RecordFirmDate
IMMULITE® 2000 BR-MA (K233946)Siemens Healthcare Diagnostics Products, Ltd.2024-03-13
IMMULITE/IMMULITE 1000 OM-MA, IMMULITE 2000 OM-MA (K213510)Siemens Healthcare Diagnostics Products, Ltd.2023-09-08
IMMULITE® 2000 Cortisol (K202826)Siemens Healthcare Diagnostics Products, Ltd.2021-01-15
IMMULITE/IMMULITE® 1000 Cortisol (K203270)Siemens Healthcare Diagnostics Products, Ltd.2021-01-15